Abstract Objective: Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of chronic liver disease worldwide and is largely driven by chronic inflammation and hepatic immune dysregulation. The receptor activator of nuclear factor-κB ligand (RANKL) is a master regulator of bone metabolism with emerging immunomodulatory functions. Although growing evidence links the RANK-RANKL-OPG axis to MASH pathophysiology, whether RANKL blockade attenuates MASH development remains unclear.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ningjia
Contact Ningjia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack